Homeopathy for Prevention of Atrial Fibrillation After Aortocoronary Bypass Surgery

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00861237

Enrollment

Registered

2009-03-13

Start date

2008-07-31

Completion date

2017-11-30

Last updated

2018-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Nux vomica, homeopathy, heart lung machine, heart surgery, postoperatively studied

Brief summary

After heart surgery, about 30% of patients suffer from atrial fibrillation. Patients are randomized into two groups receiving either potentized Strychnos Nux vomica or placebo under double blind conditions. Postoperatively, ECGs are done to monitor cardiac rhythm.

Detailed description

Preoperatively, patients receive potentized Nux vomica or placebo sublingually. Then, patients are observed regarding atrial fibrillation postsurgical. The difference between the group of patients with and without nux vomica is recorded.

Interventions

DRUGNux vomica (active comparator)

Patients receive Nux vomica in a homeopathic potentiation

DRUGPlacebo (placebo comparator)

Patients receive Placebo looking similar to active drug

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Patients before elective Heart valve - or aortocoronary by pass surgery with heart-lung-machine.

Exclusion criteria

* Pregnant patients * Patients with preoperative atrial fibrillation and/or hyperthyreosis

Design outcomes

Primary

Measure	Time frame
Frequency of atrial fibrillation after heart surgery with heart lung machine	24 months

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026